Novavax reported $147.14M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Adma Biologics USD 114.5M 24.66M Mar/2026
Agenus USD 33.7M 500K Mar/2026
AstraZeneca USD 15.38B 90M Jun/2026
BioCryst Pharmaceuticals USD 406.56M 247.16M Dec/2025
Geron USD 57.48M 5.64M Jun/2026
GlaxoSmithKline GBP 8.41B 781M Jun/2026
MannKind USD 90.2M 21.76M Mar/2026
Merck USD 16.6B 310M Jun/2026
Minerva Neurosciences USD 0 0 Sep/2024
Moderna USD 100M 289M Jun/2026
Novartis USD 13.11B 750M Mar/2026
Novavax USD 147.14M 76.69M Dec/2025
Pfizer USD 15.03B 530M Jun/2026
Sanofi EUR 11.95B 710M Jun/2026
Sarepta Therapeutics USD 730.8M 287.9M Mar/2026
TG Therapeutics USD 240.34M 45.54M Jun/2026